Building a true strategy about your pharmaceutical drugability 
Years of experience
Clients
Studied molecules
Clarified strategies in terms of scope and prioritisation between studies
Shortened timelines for selecting higher value drug candidates
Lower risk in early development programs and optimisation of R&D costs
Higher project team autonomy in regulatory preclinical and clinical development
Enhanced chances for a much higher project valorisation
Latest news
Le mot du président AFSSI
A découvrir... Joël Vacus, CEO de Drugabilis et président de l’AFSSI depuis 2019, fait le bilan de l’action de l’association au cours de sa mandature. Joël revient notamment sur les deux grandes...
more news>